- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 33,198
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypochondroplasia
- Interventions
- infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Asthma
- Interventions
- Dexamethasone, placebo
- Drug
- Lead sponsor
- Geoffrey W Jara-Almonte
- Other
- Eligibility
- 18 Months to 20 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Food Intake
- Interventions
- Placebo spray, Diltiazem
- Other · Drug
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
- Interventions
- OGX-427 600 mg, OGX-427 1000 mg, Placebo, Gemcitabine, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Achieve Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 9 more
- Conditions
- Heart Diseases, Hypertension, Pulmonary
- Interventions
- tezosentan, placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 9
- States / cities
- Stanford, California • New York, New York • Durham, North Carolina + 5 more
- Conditions
- Healthy
- Interventions
- ME1100 inhalation solution, ME1100 placebo inhalation solution
- Drug
- Lead sponsor
- Meiji Seika Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Obesity, Quality of Life
- Interventions
- LactoWise®, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Postoperative Nausea and Vomiting (PONV)
- Interventions
- TAK-951, Ondansetron, Ondansetron Placebo, TAK-951 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Sheffield, Alabama • Pasadena, California • Tamarac, Florida + 4 more
- Conditions
- Peripheral Neuropathy
- Interventions
- MIRE, Sham Device
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Gastroesophageal Reflux Disease, Heartburn
- Interventions
- Amiloride, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Ileus
- Interventions
- Alvimopan
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Exton, Pennsylvania
- Conditions
- Bipolar Disorder
- Interventions
- Placebo, Metformin
- Drug
- Lead sponsor
- Cynthia Calkin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Major Depressive Disorder
- Interventions
- 5-hydroxytryptophan and Creatine, Placebo control
- Drug · Other
- Lead sponsor
- Brent Michael Kious, MD, PhD
- Other
- Eligibility
- 25 Years to 40 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Influenza
- Interventions
- GSK Biologicals' FluLaval®, Placebo (saline), GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 19 Years to 40 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Milford, Massachusetts • Salisbury, North Carolina • Winston-Salem, North Carolina
- Conditions
- Nephrolithiasis
- Interventions
- Bupivacaine, Normal saline
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- 100mg SPN-812, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 48 Months to 69 Months
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 54
- States / cities
- Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more
- Conditions
- Crohn's Disease
- Interventions
- Fecal Microbial transplant, Normal Saline, rifaximin+omeprazole+miralax
- Biological · Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Parkinson's Disease, Mild Cognitive Impairment
- Interventions
- MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)
- Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Hines, Illinois
- Conditions
- Migraine, Irritable Bowel Syndrome, Headache, Migraine
- Interventions
- Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483), Placebo Comparator: Placebo
- Dietary Supplement · Other
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Gingivitis, Gingival Bleeding, Dental Plaque
- Interventions
- Device: Electric Flosser, Manual toothbrush
- Device
- Lead sponsor
- Flaus, Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Noblesville, Indiana
- Conditions
- Acute Pain, Wound Care, Posttraumatic Stress Disorder
- Interventions
- ketamine, Fentanyl
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes, Effects of Liraglutide Administration on Brain Activity, Weight Loss, Hunger
- Interventions
- Liraglutide, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts